Abstract
Taxanes (paclitaxel and docetaxel) are currently used to treat ovarian, breast, lung, and head and neck cancers. Despite its clinical success taxane-based treatment could be significantly improved by identifying those patients whose tumors are more likely to present a clinical response. In this mini-review we discuss the accumulating evidence indicating that the breast and ovarian cancer susceptibility gene product BRCA1 mediates cellular response to taxanes. We review data from in vitro, animal, and clinical studies, and discuss them in context of response to therapy. We argue that levels of BRCA1 in tumors may provide a predictive marker for the response to treatment with taxanes. In addition, the study of the role of BRCA1 in the mechanism of action of taxanes might reveal alternative approaches to avoid resistance.
Keywords: Taxol, taxane, BRCA1, cancer, biomarker, microtubule, tubulin, chemotherapy
Anti-Cancer Agents in Medicinal Chemistry
Title: Can the Status of the Breast and Ovarian Cancer Susceptibility Gene 1 Product (BRCA1) Predict Response to Taxane-Based Cancer Therapy?
Volume: 9 Issue: 5
Author(s): J. Thomas DeLigio, Aneliya Velkova, Diego A.R. Zorio and Alvaro N.A. Monteiro
Affiliation:
Keywords: Taxol, taxane, BRCA1, cancer, biomarker, microtubule, tubulin, chemotherapy
Abstract: Taxanes (paclitaxel and docetaxel) are currently used to treat ovarian, breast, lung, and head and neck cancers. Despite its clinical success taxane-based treatment could be significantly improved by identifying those patients whose tumors are more likely to present a clinical response. In this mini-review we discuss the accumulating evidence indicating that the breast and ovarian cancer susceptibility gene product BRCA1 mediates cellular response to taxanes. We review data from in vitro, animal, and clinical studies, and discuss them in context of response to therapy. We argue that levels of BRCA1 in tumors may provide a predictive marker for the response to treatment with taxanes. In addition, the study of the role of BRCA1 in the mechanism of action of taxanes might reveal alternative approaches to avoid resistance.
Export Options
About this article
Cite this article as:
DeLigio Thomas J., Velkova Aneliya, Zorio A.R. Diego and Monteiro N.A. Alvaro, Can the Status of the Breast and Ovarian Cancer Susceptibility Gene 1 Product (BRCA1) Predict Response to Taxane-Based Cancer Therapy?, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (5) . https://dx.doi.org/10.2174/187152009788451798
DOI https://dx.doi.org/10.2174/187152009788451798 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine HHT in Childhood: Screening for Special Patients
Current Pharmaceutical Design Ceramide in Chemotherapy of Tumors
Recent Patents on Anti-Cancer Drug Discovery The Targets of Curcumin
Current Drug Targets Development of personalized molecular therapy for acute myeloid leukemia
Current Pharmaceutical Biotechnology CYLD-Mediated Signaling and Diseases
Current Drug Targets The History of the HSV Amplicon: From Naturally Occurring Defective Genomes to Engineered Amplicon Vectors
Current Gene Therapy Mechanisms of Resistance to Photodynamic Therapy
Current Medicinal Chemistry Photodynamic Therapy: The Light Treatment for Cutaneous Non- Melanoma Malignancies
Current Cancer Therapy Reviews Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy
Protein & Peptide Letters Spatial and Temporal Simulation of Human Evolution. Methods, Frameworks and Applications
Current Genomics Recent Patents on Biomedical Devices and Nanomaterials for Hyperthermal Therapy of Cancer
Recent Patents on Nanomedicine Sulfotransferase 1A1 as a Biomarker for Susceptibility to Carcinogenesis: From Molecular Genetics to the Role of Dietary Flavonoids
Current Drug Metabolism From Natural Products to Designer Drugs: Development and Molecular Mechanisms Action of Novel Anti-Microtubule Breast Cancer Therapeutics
Current Topics in Medicinal Chemistry Novel and Emerging Targeted Therapies of Colorectal Cancer
Current Clinical Pharmacology ras Genes and Human Cancer: Different Implications and Different Roles
Current Genomics Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry A Role of DEAD-Box RNA Helicase rck/p54 in Cancer Cells
Current Drug Therapy Immune Receptors, Cadherins and their Interactions
Current Immunology Reviews (Discontinued) Serum HSP90-Alpha and Oral Squamous Cell Carcinoma: A Prospective Biomarker
Protein & Peptide Letters